Sleep Quality & Psoriatic Arthritis
For people living with psoriatic arthritis (PsA), the comfort of a good night's sleep may feel out of reach for many.
Read more →What's hot
View all perspectives
What's Hot
Ultrasound in PsA
Dr. Arthur Kavanaugh discusses abstract 2206 presented at ACR22 in Philadelphia. Abstract 2206: Understanding Inter-rater Variability in Scoring of Entheseal Lesions: Results from the Diagnostic Ultrasound Enthesitis Tool (DUET) Study
Watch video →
Tapering TNFi in nonradiographic AxSpA
Dr. Peter Nash at ACR22 Convergence in Philadelphia, PA.
Watch video →
Sunday (Day 2): ACR 22 Daily Recap
ACR 2022 Daily Recap for Sunday, November 13th. Panelists: Drs. Robert Chao, Antoni Chan, Bella Mehta, Janet Pope, Yuz Yusof, Cassy Sims, Akhil Sood, Sheila Reyes and Jack Cush.
Watch video →
Spondyloarthritis: Novel Therapies, Diagnostic Dilemmas and Depression
Dr. Lianne Gensler discusses the following abstracts presented at ACR22 Convergence. Abstracts 1597, 1598, 1599 (treatment) and 1613, 1609 and 1614 (diagnosis and outcomes)
Watch video →
Deucravacitinib in PsA
Dr. Arthur Kavanaugh discusses abstract 1598 at ACR22 Convergence in Philadelphia. Abstract 1598: Safety and Efficacy of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients with Psoriatic Arthritis: 52-Week Results from a Randomized Phase 2 Trial
Watch video →
Sarilumab in Polymyalgia Rheumatica: Results from SAPHYR Trial
Dr. Michael Putman interviews Dr. Robert Speira about abstract 1676 presented at the ACR22 Convergence meeting in Philadelphia, PA. Abstract 1676: Sarilumab in Patients with Relapsing Polymyalgia Rheumatica: A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Trial (SAPHYR)
Watch video →
PET CT Imaging to Define Risk of Progression from PSO to PsA
Dr. Peter Nash discusses Abstract 1018 at ACR22 Convergence.
Watch video →
ACR22 Daily Recap: Saturday Recap
Panelists: Drs. Jack Cush, Michael Putman, Eric Dein, Patricia Harkins and Rachel Tate.
Watch video →
Dr. Rachel Tate uptoTate
3 years 1 month ago
Dr. @Drbeckyg reminds us that self-reported, RA patient completed joint counts are good for tender and ok for swollen. Check out her videos for teaching joint counts to your patients - all under 8 minutes in total. #ACR22 @RheumNow https://t.co/E2wBsNFS12
Richard Conway RichardPAConway
3 years 1 month ago
Makol @AshimaMakol et al. Digital ischaemia 79% SSc patients. Higher risk - digital occlusive arterial disease on laser doppler flowmetry Macrovascular disease on US, ILD, calcinosis, pericardial effusion. @RheumNow #ACR22 Abstr#1518 https://t.co/DJTtCVD0Oe https://t.co/9i4Vivir8q
Richard Conway RichardPAConway
3 years 1 month ago
Chen et al. Tofacitinib in new-onset PMR. Tofa (No GC!) vs standard GC. Equally effective! @RheumNow #ACR22 Abstr#1107 #ACRbest https://t.co/w3WJ8YZsyz https://t.co/qmt1RUAAGB
Dr. Antoni Chan synovialjoints
3 years 1 month ago
Pike M Abstract 1113. Remibrutinib (LOU064) in Sjögren’s Syndrome: Safety and Efficacy Results from a 24‑Week Placebo-controlled Proof-of-Concept Study #ACRBest #ACR22 @RheumNow
Dr. Rachel Tate uptoTate
3 years 1 month ago
"Telemedicine is not inferior to F2F visits in Rheumatology!" Dr. @RheumNow. While this may be true, it takes patient education and setting expectations about the visit (no driving during appointment!) #ACR22 @KDAO2011
Richard Conway RichardPAConway
3 years 1 month ago
Torgutalp et al. Higher NSAID intake associated reduced spinal progression in AxSpA esp. r-AxSpA. Cox-2 may have greater effect than other NSAIDs. @RheumNow #ACR22 Abstr#1492 https://t.co/bGH6bBo7AD https://t.co/XBFV410Y2p
Aurelie Najm AurelieRheumo
3 years 1 month ago
Baker et al, Corevitas registry in 7000+ RA pts
Pts w/ moderate pain HR 1.37
Pts w/ severe pain HR 1.42
more likely to switch to diff MOA b/tsDMARD
Adjusted for confounders incl DA
Time we address pain separately to spare MAOs in a lifelong disease!
Abs#1590 #ACR22 @Rheumnow https://t.co/RP8Rb6bp9m
Richard Conway RichardPAConway
3 years 1 month ago
Joerns et al. Baseline IL-17 higher in RD-ILD vs IPF. Low IL-13 assoc shorter progression free survival HR 17.36 @RheumNow #ACR22 Abstr#1109 https://t.co/I8R3SrxNfV https://t.co/he1A3SYDp0
Richard Conway RichardPAConway
3 years 1 month ago
Goldman et al. RTX, TCZ in SSc ILD. 129 patients, 87 RTX, 32 TCZ, 10 both. Median changes in %FVC and %DLCO pre-and post-treatment were +0.35% and -0.8% for rituximab and -0.9% and +0.2% for tocilizumab. Majority stable/improved @RheumNow #ACR22 Abstr#1520 https://t.co/ydY5FGEYnQ https://t.co/O9QD7nkjdZ
Dr. Rachel Tate uptoTate
3 years 1 month ago
"Tweeting a conference is hard work!" @rheum_cat is right! Shout out to all of the #rheumtwitter, RN reporters, conference attendees and all of those tweeting from home! #ACR22 @RheumNow
Richard Conway RichardPAConway
3 years 1 month ago
Avouac @AvouacJerome et al. Maintaining complete B cell depletion assoc RTX efficacy in CTD-ILD. % with FVC improvement - 67% vs 50% for B cell depletion 1 year, 89% vs 50% B cell depletion last infusion. @RheumNow #ACR22 Abstr#1527 https://t.co/xr7DHOHci2 https://t.co/2n95PgzLxN
Richard Conway RichardPAConway
3 years 1 month ago
Reid et al. Emphysema, lymphadenopathy, consolidative opacities on CT pre-ICI increase risk of ICI pneumonitis. Pul nodules decrease risk. GERD, asthma in history also increase risk. @RheumNow #ACR22 Abstr#1108 https://t.co/ZD8ibsECnV https://t.co/FVnQgn2I2S
Dr. John Cush RheumNow
3 years 1 month ago
Day 1 Report
The masses have returned to #ACR22, a hybrid meeting that began Saturday in Philadelphia. Throngs and gaggles of MSK wannabees crammed the ballrooms and rushed the exhibits as they relived the rheumatologic meeting we once knew.
https://t.co/8GjRAT7Zuy https://t.co/vyXRcVxOpo
Poster Hall